Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/87791| Title: | Primidone |
| Other Titles: | Atlas of epilepsies |
| Authors: | Mifsud, Janet |
| Keywords: | Primidone Barbiturates -- Physiological effect Barbiturates -- Toxicology |
| Issue Date: | 2010 |
| Publisher: | Springer |
| Citation: | Mifsud, J. (2010). Primidone. In: C. P. Panayiotopoulos (Ed.), Atlas of epilepsies (pp. 1825-1827). Cham: Springer. |
| Abstract: | Chemical name: 5-ethyldihydro-5-phenyl-4,6 (1H, 5H) pyrimidinedione. The effectiveness of primidone in epilepsy was first demonstrated in 1949 (Whitty 1953). It was introduced a year later by the Imperial Chemical Industry (ICI) (now known as AstraZeneca) in the UK and Germany. In 1952, its effectiveness in the treatment of patients with idiopathic generalized epilepsy was demonstrated, and it was introduced in 1954 (as Mysoline®) by Wyeth in the USA (Williams 1956). [excerpt] |
| URI: | https://www.um.edu.mt/library/oar/handle/123456789/87791 |
| Appears in Collections: | Scholarly Works - FacM&SCPT |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| atlas-of-epilepsies-Primidone.pdf Restricted Access | 61.84 MB | Adobe PDF | View/Open Request a copy |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.